ClinicalTrials.gg
CompletedNCT06011733BE SHININGUpdated Jun 26, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Placebo and Bimekizumab in Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 18 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
12th of 20
133 · median 161
Started
2023
the only one that year
Phase 3
10 of 20
2 open now
Registered
14th of 20
by date
Lead sponsor
13 of 20
UCB Biopharma SRL

Among the 20 studies testing bimekizumab in Psoriasis, this one is the 12th largest by enrollment, is the only one that started in 2023, is one of 10 in phase 3, and was the 14th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).

03

Conditions studied

  • Chronic Plaque Psoriasis
  • Moderate to Severe Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • PSO
  • Bimekizumab
  • Chinese Adults Study Participants
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant is Chinese male or female ≥18 years of age
  • Study participant has plaque psoriasis (PSO) for ≥6 months prior to the Screening Visit
  • Study participant has Psoriasis Area and Severity Index (PASI) ≥12 and body surface area (BSA) affected by PSO ≥10% and Investigator's Global Assessment (IGA) score ≥3 on a 5-point scale.
  • Study participant is a candidate for systemic PSO therapy and/or phototherapy
  • Female study participants must be or permanently sterilized or if must be willing to use protocol defined highly effective method of throughout the duration of the study until 17 weeks after last administration of medicinal product (IMP) and have a negative pregnancy test at Screening and prior to first dose

Exclusion criteria

Exclusion Criteria:

  • Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 17 weeks following the final dose of IMP
  • Study participant has a form of PSO other than chronic plaque-type (eg, pustular, erythrodermic, guttate, or drug-induced PSO)
  • Study participant has an active infection or history of infection(s) as defined in the protocol
  • Study participant has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection.Study participant has a past history of active TB involving any organ system unless adequately treated and is proven to be fully recovered upon consult with a TB specialist
  • Study participant has a diagnosis of inflammatory conditions other than PSO vulgaris or psoriatic arthritis (PsA)
  • Study participant has presence of significant uncontrolled neuropsychiatric disorder. Study participants with history of suicide attempt within the 5 years prior to the Screening Visit must be excluded. Study participants with history of suicide attempt more than 5 years prior to the Screening Visit must be evaluated by a mental health care practitioner before enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    bimekizumab

    Study participants randomized to this arm will receive bimekizumab (BKZ) dosage regimen 1 in the Initial Treatment Period (16 weeks) and switch to dosage regimen 2 and placebo to maintain the blinding in the Maintenance Treatment Period (16 weeks).

    Other: Placebo · Drug: Bimekizumab

  • Placebo comparator
    placebo

    Study participants randomized to this arm will receive placebo comparator in the Initial Treatment Period (16 weeks) and switch to bimekizumab dosage regimen 1 in the Maintenance Treatment Period (16 weeks).

    Other: Placebo · Drug: Bimekizumab

Interventions

  • OtherPlacebo

    Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.

  • Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.

    Also known as: BKZ

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Psoriasis Area Severity Index 90 (PASI90) Response at Week 16

    PASI90:at least 90% improvement in PASI score from Baseline (latest measurement before/at first IMP dose). Body divided in 4 areas: head, upper extremities, trunk and lower extremities and each area scored for redness, thickness, and scaling (each on 5-point scale: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked). Determining percentage of skin covered with PSO for each body areas and converting to 0 to 6 scale (0=none; 1=1% to less than \[\<\] 10% affected; 2=10% to \<30% affected; 3=30% to \<50% affected; 4=50% to \<70% affected; 5=70% to \<90% affected; 6=90% to 100% affected). Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of the person's affected skin for respective section. Minimum PASI score 0=no disease, maximum score 72=maximal disease. Higher score indicated increased disease severity. Percentage of participants data was rounded to one decimal place.

    Time frame: Week 16

  2. Percentage of Participants With Investigator´s Global Assessment (IGA) 0/1 Response at Week 16

    The IGA measured the overall psoriasis severity using a 5-point scale (0-4), where 0=clear - no signs of psoriasis; post-inflammatory hyperpigmentation may be present, 1=almost clear - no thickening; normal to pink coloration; no to minimal focal scaling, 2=mild - just detectable to mild thickening; pink to light red coloration and predominately fine scaling, 3=moderate - clearly distinguishable to moderate thickening; dull to bright red, moderate scaling and 4=severe - severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Percentage of Participants with Investigator´s Global Assessment (IGA) 0/1 response at Week 16 is reported here. The percentage of participants data was rounded to one decimal place.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With PASI75 Response at Week 4

    PASI75 response: at least 75% improvement in PASI score from Baseline (latest measurement before/at first IMP dose). Body divided into 4 areas: head, upper extremities, trunk and lower extremities and each area scored for redness, thickness, and scaling on a 5-point scale: 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked). Percentage of skin covered with PSO for each region was converted to 0 to 6 scale (0=none; 1=1% to \<10% affected; 2=10% to \<30% affected; 3=30% to \<50% affected; 4=50% to \<70% affected; 5=70% to \<90% affected; 6=90% to 100% affected). Final PASI= average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of the person's affected skin for respective section. Minimum PASI score 0= no disease, the maximum PASI score 72= maximal disease. Higher score indicated increased disease severity. Percentage of participants data was rounded to one decimal place.

    Time frame: Week 4

  2. Percentage of Participants With PASI100 Response at Week 16

    PASI100: 100% improvement in PASI score from Baseline (latest measurement before/at first IMP dose). Body divided into 4 areas: head, upper extremities, trunk and lower extremities and each region scored for redness, thickness, and scaling (each on a 5 point scale: 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked). Determining percentage of skin covered with PSO for each of body areas and 0 to 6 scale (0=none; 1=1% to \<10% affected; 2=10% to \<30% affected; 3=30% to \<50% affected; 4=50% to \<70% affected; 5=70% to \<90% affected; 6=90% to 100% affected). Final PASI= average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of the person's affected skin for respective section. Minimum PASI score= 0 (no disease), the maximum PASI score= 72 (maximal disease). Higher score indicated increased disease severity. The percentage of participants data was rounded to one decimal place.

    Time frame: Week 16

  3. Percentage of Participants With Patient Symptom Diary (PSD) Psoriasis Symptom and Impact Measure (P-SIM) Response for Itch at Week 16

    The PSD (P-SIM) consisted of 14 items, measuring the following PSO related signs, symptoms, and functional impacts: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment, and choice of clothing. The PSD (P-SIM) was designed to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours. Each item was assessed for severity/impact level on a 0-10 point numeric rating scale (NRS) where 0 (no symptom/ impact) and 10 (very severe symptom/ worst impact). PSD (P-SIM) response for itch at Week 16: participants were considered responders if itch score improved (decreased) by greater than or equal to (\>=) 4 points from Baseline to Week 16 and study participant had not discontinued the investigational medicinal product (IMP) prior to Week 16. Percentage of participants data was rounded to one decimal place.

    Time frame: Week 16

  4. Percentage of Participants With PSD P-SIM Response for Pain at Week 16

    The PSD (P-SIM) consisted of 14 items, measuring the following PSO related signs, symptoms, and functional impacts: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment, and choice of clothing. The PSD (P-SIM) was designed to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours. Each item was assessed for severity/impact level on a 0-10 point NRS where 0 (no symptom/ impact) and 10 (very severe symptom/ worst impact. PSD (P-SIM) response for pain at Week 16: participants were considered responders if pain score improved (decreased) by \>=4 points from Baseline to Week 16, and the study participant had not discontinued IMP prior to Week 16. The percentage of participants data was rounded to one decimal place.

    Time frame: Week 16

  5. Percentage of Participants With PSD P-SIM Response for Scaling at Week 16

    The PSD (P-SIM) consisted of 14 items, measuring the following PSO related signs, symptoms, and functional impacts: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment, and choice of clothing. The PSD (P-SIM) was designed to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours. Each item was assessed for severity/impact level on a 0-10 point NRS where 0 (no symptom/impact) and 10 (very severe symptom/worst impact. PSD (P-SIM) response for scaling at Week 16: participants were considered responders if scaling score had improved (decreased) by \>=4 points from Baseline to Week 16, and the study participant had not discontinued IMP prior to Week 16. The percentage of participants data was rounded to one decimal place.

    Time frame: Week 16

  6. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 16

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. TEAEs through Week 16 were defined as those AEs that had a start date on or following the first dose of IMP through Week 16. The percentage of participants data was rounded to one decimal place.

    Time frame: From Baseline to End of Initial Treatment Period (up to Week 16)

  7. Percentage of Participants With Serious TEAEs Through Week 16

    A SAE was defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires in patient hospitalisation or prolongation of existing hospitalisation, results in persistent disability or incapacity, is a congenital anomaly or birth defect, other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above. The percentage of participants data was rounded to one decimal place.

    Time frame: From Baseline to End of Initial Treatment Period (up to Week 16)

  8. Percentage of Participants With TEAEs Leading to Permanent Discontinuation of IMP Through Week 16

    Percentage of Participants with TEAEs leading to permanent discontinuation of IMP through Week 16 was reported. An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. TEAEs through Week 16 were defined as those AEs that had a start date on or following the first dose of IMP through Week 16. The percentage of participants data was rounded to one decimal place.

    Time frame: From Baseline to End of Initial Treatment Period (up to Week 16)

07

Results

Posted Feb 20, 2026

Participant flow

The study started to enroll participants in October 2023 and concluded in February 2025.

ITP (up to Week 16)
Participant flow — ITP (up to Week 16)
MilestonePlacebo/Bimekizumab (BKZ) Dosage Regimen 1BKZ Dosage Regimen 1/BKZ Dosage Regimen 2
Started33100
Completed3097
Not completed33
Withdrew: Adverse event11
Withdrew: Lack of efficacy10
Withdrew: Consent withdrawn by study participants (not due to adverse event)10
Withdrew: Other (poor compliance, missed follow-up visit)01
Withdrew: Other (risks outweighed the potential benefits)01
MTP (Week 16 to Week 32)
Participant flow — MTP (Week 16 to Week 32)
MilestonePlacebo/Bimekizumab (BKZ) Dosage Regimen 1BKZ Dosage Regimen 1/BKZ Dosage Regimen 2
Started3096
Completed3089
Not completed07
Withdrew: Adverse event06
Withdrew: Consent withdrawn by study participants (not due to adverse event)01

Outcome measures

PrimaryPercentage of Participants With Psoriasis Area Severity Index 90 (PASI90) Response at Week 16

PASI90:at least 90% improvement in PASI score from Baseline (latest measurement before/at first IMP dose). Body divided in 4 areas: head, upper extremities, trunk and lower extremities and each area scored for redness, thickness, and scaling (each on 5-point scale: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked). Determining percentage of skin covered with PSO for each body areas and converting to 0 to 6 scale (0=none; 1=1% to less than \[\<\] 10% affected; 2=10% to \<30% affected; 3=30% to \<50% affected; 4=50% to \<70% affected; 5=70% to \<90% affected; 6=90% to 100% affected). Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of the person's affected skin for respective section. Minimum PASI score 0=no disease, maximum score 72=maximal disease. Higher score indicated increased disease severity. Percentage of participants data was rounded to one decimal place.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area Severity Index 90 (PASI90) Response at Week 16
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With Psoriasis Area Severity Index 90 (PASI90) Response at Week 163.094.0
Statistical analysis
  • ITP: Placebo vs ITP: BKZ Dosage Regimen 1 · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups are based on the CMH test from the general association.) · Odds ratio (or): 501.333 · 95% CI 58.125 to 4324.033Odds ratio of PASI 90 for BKZ Dosage Regimen 1 compared with Placebo group using Wald test.
PrimaryPercentage of Participants With Investigator´s Global Assessment (IGA) 0/1 Response at Week 16

The IGA measured the overall psoriasis severity using a 5-point scale (0-4), where 0=clear - no signs of psoriasis; post-inflammatory hyperpigmentation may be present, 1=almost clear - no thickening; normal to pink coloration; no to minimal focal scaling, 2=mild - just detectable to mild thickening; pink to light red coloration and predominately fine scaling, 3=moderate - clearly distinguishable to moderate thickening; dull to bright red, moderate scaling and 4=severe - severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Percentage of Participants with Investigator´s Global Assessment (IGA) 0/1 response at Week 16 is reported here. The percentage of participants data was rounded to one decimal place.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator´s Global Assessment (IGA) 0/1 Response at Week 16
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With Investigator´s Global Assessment (IGA) 0/1 Response at Week 163.092.0
Statistical analysis
  • ITP: Placebo vs ITP: BKZ Dosage Regimen 1 · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups are based on the CMH test from the general association.) · Odds ratio (or): 368.000 · 95% CI 44.286 to 3057.940Odds ratio of IGA 0/1 for BKZ Dosage Regimen 1 compared with Placebo group using Wald test.
SecondaryPercentage of Participants With PASI75 Response at Week 4

PASI75 response: at least 75% improvement in PASI score from Baseline (latest measurement before/at first IMP dose). Body divided into 4 areas: head, upper extremities, trunk and lower extremities and each area scored for redness, thickness, and scaling on a 5-point scale: 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked). Percentage of skin covered with PSO for each region was converted to 0 to 6 scale (0=none; 1=1% to \<10% affected; 2=10% to \<30% affected; 3=30% to \<50% affected; 4=50% to \<70% affected; 5=70% to \<90% affected; 6=90% to 100% affected). Final PASI= average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of the person's affected skin for respective section. Minimum PASI score 0= no disease, the maximum PASI score 72= maximal disease. Higher score indicated increased disease severity. Percentage of participants data was rounded to one decimal place.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With PASI75 Response at Week 4
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With PASI75 Response at Week 43.074.0
Statistical analysis
  • ITP: Placebo vs ITP: BKZ Dosage Regimen 1 · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 91.077 · 95% CI 11.844 to 700.362Odds ratio of PASI 75 for BKZ Dosage Regimen 1 compared with Placebo group using Wald test.
SecondaryPercentage of Participants With PASI100 Response at Week 16

PASI100: 100% improvement in PASI score from Baseline (latest measurement before/at first IMP dose). Body divided into 4 areas: head, upper extremities, trunk and lower extremities and each region scored for redness, thickness, and scaling (each on a 5 point scale: 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked). Determining percentage of skin covered with PSO for each of body areas and 0 to 6 scale (0=none; 1=1% to \<10% affected; 2=10% to \<30% affected; 3=30% to \<50% affected; 4=50% to \<70% affected; 5=70% to \<90% affected; 6=90% to 100% affected). Final PASI= average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of the person's affected skin for respective section. Minimum PASI score= 0 (no disease), the maximum PASI score= 72 (maximal disease). Higher score indicated increased disease severity. The percentage of participants data was rounded to one decimal place.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With PASI100 Response at Week 16
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With PASI100 Response at Week 16065.0
Statistical analysis
  • ITP: Placebo vs ITP: BKZ Dosage Regimen 1 · Fisher Exact · p = <0.001 (P-values for the comparison of treatment groups are based on the Fisher's exact test.)
SecondaryPercentage of Participants With Patient Symptom Diary (PSD) Psoriasis Symptom and Impact Measure (P-SIM) Response for Itch at Week 16

The PSD (P-SIM) consisted of 14 items, measuring the following PSO related signs, symptoms, and functional impacts: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment, and choice of clothing. The PSD (P-SIM) was designed to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours. Each item was assessed for severity/impact level on a 0-10 point numeric rating scale (NRS) where 0 (no symptom/ impact) and 10 (very severe symptom/ worst impact). PSD (P-SIM) response for itch at Week 16: participants were considered responders if itch score improved (decreased) by greater than or equal to (\>=) 4 points from Baseline to Week 16 and study participant had not discontinued the investigational medicinal product (IMP) prior to Week 16. Percentage of participants data was rounded to one decimal place.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Patient Symptom Diary (PSD) Psoriasis Symptom and Impact Measure (P-SIM) Response for Itch at Week 16
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With Patient Symptom Diary (PSD) Psoriasis Symptom and Impact Measure (P-SIM) Response for Itch at Week 168.084.1
SecondaryPercentage of Participants With PSD P-SIM Response for Pain at Week 16

The PSD (P-SIM) consisted of 14 items, measuring the following PSO related signs, symptoms, and functional impacts: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment, and choice of clothing. The PSD (P-SIM) was designed to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours. Each item was assessed for severity/impact level on a 0-10 point NRS where 0 (no symptom/ impact) and 10 (very severe symptom/ worst impact. PSD (P-SIM) response for pain at Week 16: participants were considered responders if pain score improved (decreased) by \>=4 points from Baseline to Week 16, and the study participant had not discontinued IMP prior to Week 16. The percentage of participants data was rounded to one decimal place.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With PSD P-SIM Response for Pain at Week 16
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With PSD P-SIM Response for Pain at Week 1614.386.1
SecondaryPercentage of Participants With PSD P-SIM Response for Scaling at Week 16

The PSD (P-SIM) consisted of 14 items, measuring the following PSO related signs, symptoms, and functional impacts: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment, and choice of clothing. The PSD (P-SIM) was designed to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours. Each item was assessed for severity/impact level on a 0-10 point NRS where 0 (no symptom/impact) and 10 (very severe symptom/worst impact. PSD (P-SIM) response for scaling at Week 16: participants were considered responders if scaling score had improved (decreased) by \>=4 points from Baseline to Week 16, and the study participant had not discontinued IMP prior to Week 16. The percentage of participants data was rounded to one decimal place.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With PSD P-SIM Response for Scaling at Week 16
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With PSD P-SIM Response for Scaling at Week 1620.091.6
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 16

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. TEAEs through Week 16 were defined as those AEs that had a start date on or following the first dose of IMP through Week 16. The percentage of participants data was rounded to one decimal place.

Time frame:
From Baseline to End of Initial Treatment Period (up to Week 16)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 16
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 1651.562.0
SecondaryPercentage of Participants With Serious TEAEs Through Week 16

A SAE was defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires in patient hospitalisation or prolongation of existing hospitalisation, results in persistent disability or incapacity, is a congenital anomaly or birth defect, other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above. The percentage of participants data was rounded to one decimal place.

Time frame:
From Baseline to End of Initial Treatment Period (up to Week 16)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious TEAEs Through Week 16
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With Serious TEAEs Through Week 169.11.0
SecondaryPercentage of Participants With TEAEs Leading to Permanent Discontinuation of IMP Through Week 16

Percentage of Participants with TEAEs leading to permanent discontinuation of IMP through Week 16 was reported. An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. TEAEs through Week 16 were defined as those AEs that had a start date on or following the first dose of IMP through Week 16. The percentage of participants data was rounded to one decimal place.

Time frame:
From Baseline to End of Initial Treatment Period (up to Week 16)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Permanent Discontinuation of IMP Through Week 16
percentage of participantsITP: PlaceboITP: BKZ Dosage Regimen 1
Percentage of Participants With TEAEs Leading to Permanent Discontinuation of IMP Through Week 163.01.0

Adverse events

Collected over From Baseline through the final dose (Week 28) of IMP + 119 days (covering the 17-week SFU Visit, ie, up to 45 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ITP: Placebo0/33 (0%)3/33 (9.1%)7/33 (21.2%)
ITP: BKZ Dosage Regimen 10/100 (0%)1/100 (1%)31/100 (31%)
ITP+MTP: BKZ Dosage Regimen 10/130 (0%)4/130 (3.1%)37/130 (28.5%)
ITP+MTP: BKZ Dosage Regimen 20/96 (0%)4/96 (4.2%)20/96 (20.8%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventITP: PlaceboITP: BKZ Dosage Regimen 1ITP+MTP: BKZ Dosage Regimen 1ITP+MTP: BKZ Dosage Regimen 2
Femur fractureInjury, poisoning and procedural complications1/330/1000/1300/96
Radius fractureInjury, poisoning and procedural complications1/330/1000/1300/96
Ovarian cyst torsionReproductive system and breast disorders1/330/1000/1300/96
Gastritis erosiveGastrointestinal disorders0/330/1000/1301/96
IleusGastrointestinal disorders0/330/1000/1301/96
Chemical poisoningInjury, poisoning and procedural complications0/330/1000/1301/96
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/330/1000/1301/96
Tendon ruptureInjury, poisoning and procedural complications0/331/1001/1300/96
Hypertrophic anal papillaGastrointestinal disorders0/330/1001/1300/96
HaemorrhoidsGastrointestinal disorders0/330/1001/1300/96
Most frequent other events
Most frequent other events
EventITP: PlaceboITP: BKZ Dosage Regimen 1ITP+MTP: BKZ Dosage Regimen 1ITP+MTP: BKZ Dosage Regimen 2
Upper respiratory tract infectionInfections and infestations2/3321/10024/1305/96
Hepatic function abnormalHepatobiliary disorders0/333/1003/1307/96
Aspartate aminotransferase increasedInvestigations2/333/1004/1301/96
HyperlipidaemiaMetabolism and nutrition disorders2/335/1005/1301/96
Injection site painGeneral disorders1/335/1007/1303/96
Latent tuberculosisInfections and infestations0/330/1000/1305/96
EczemaSkin and subcutaneous tissue disorders0/333/1004/1305/96

Baseline characteristics

The Baseline refers the Randomized Set (RS) which consisted of all randomized study participants.

Age, Continuous
Age, Continuous(years)Placebo/Bimekizumab (BKZ) Dosage Regimen 1BKZ Dosage Regimen 1/BKZ Dosage Regimen 2Total
Mean39.9 ± 13.839.8 ± 13.239.8 ± 13.3
Age, Customized
Age, Customized(Participants)Placebo/Bimekizumab (BKZ) Dosage Regimen 1BKZ Dosage Regimen 1/BKZ Dosage Regimen 2Total
18 - <65 years3296128
65 - <85 years145
>= 85 years000
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/Bimekizumab (BKZ) Dosage Regimen 1BKZ Dosage Regimen 1/BKZ Dosage Regimen 2Total
Female52934
Male287199
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/Bimekizumab (BKZ) Dosage Regimen 1BKZ Dosage Regimen 1/BKZ Dosage Regimen 2Total
Asian33100133
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/Bimekizumab (BKZ) Dosage Regimen 1BKZ Dosage Regimen 1/BKZ Dosage Regimen 2Total
Not Hispanic or Latino33100133
08

Study locations

18 sites
  • Ps0041 20023
    Beijing, China
  • Ps0041 20247
    Beijing, China
  • Ps0041 20306
    Beijing, China
  • Ps0041 20117
    Guangzhou, China
  • Ps0041 20311
    Guangzhou, China
  • Ps0041 20313
    Guangzhou, China
  • Ps0041 20022
    Hangzhou, China
  • Ps0041 20193
    Hangzhou, China
  • Ps0041 20296
    Hangzhou, China
  • Ps0041 20312
    Jinan, China
  • Ps0041 20318
    Jinan, China
  • Ps0041 20310
    Ningbo, China
  • Ps0041 20308
    Shanghai, China
  • Ps0041 20184
    Shenzhen, China
  • Ps0041 20136
    Tianjin, China
  • Ps0041 20120
    Wuhan, China
  • Ps0041 20314
    Wuxi, China
  • Ps0041 20309
    Xi'an, China
09

References and documents

Publications

  • Cai L, Man XY, Wang J, Wei A, Chen Y, Deherder D, Gao J, Hoepken B, Sun W, Lei T, Zhang J; BE SHINING Study Group. Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study. J Eur Acad Dermatol Venereol. 2026 Jun;40(6):1019-1029. doi: 10.1111/jdv.70350. Epub 2026 Feb 12. PubMed 41678327 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Feb 2025, 15 months.

Results were first posted in Feb 2026, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Aug 25, 2023
StartActual
Oct 31, 2023
Primary completionActual
Feb 5, 2025
CompletionActual
Feb 5, 2025
Results first posted
Feb 20, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06011733
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Oct 31, 2023
Primary completion
Feb 5, 2025
Completion
Feb 5, 2025
Results posted
Feb 20, 2026
Last update
Jun 26, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion